NCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
Incyte Corporation
M.D. Anderson Cancer Center
MacroGenics
National Institutes of Health Clinical Center (CC)
Incyte Corporation